Expression of melatonin receptor (MT1) and interaction between melatonin and estrogen in endometrial cancer cell line
2008
Aim: To determine the receptor subtypes of
melatoninin estrogen receptor-positive endometrial cancer cell line, Ishikawa, and the influence of
melatoninon
chemosensitivity. Methods: To confirm the subtype of
melatoninon Ishikawa cells, cells were treated with
melatoninalone and with antagonists against
melatonin receptor
luzindoleand 4-phenyl-2-propionamidotetralin (4-P-PDOT). Expression of MT1/MT2 mRNA was analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR).
Immunocytochemistryof MT1/MT2 was also performed. The effect of
melatoninagainst expression of MT1, MT2, and ERα-receptors mRNA was compared with RT-PCR. To determine whether
melatoninenhances the effect of anticancer agents,
chemosensitivitytest was performed with or without
melatonin. Results: Our study revealed that Ishikawa cells express MT1 by both RT-PCR and
immunocytochemistry. In contrast, expression of MT2 mRNA was not found. Furthermore, ERα mRNA expression was attenuated at
melatoninlevel of 1 × 10−9 M.
Chemosensitivitytest revealed that
melatoninenhanced anti-tumor effects of paclitaxel among anticancer
drugs tested. Conclusion: Based on the above results, MT1 receptor, but not MT2, is expressed in Ishikawa cells. It was also revealed that the cytostatic effect of
melatoninis partly an action mediated by MT1 receptor, and attenuation of ERα expression was predicted as the mechanism of action. Clinical application of
melatoninto biochemotherapy might be also expected.
Keywords:
-
Correction
-
Source
-
Cite
-
Save
34
References
15
Citations
NaN
KQI